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Case presentation
A 63-year-old woman was admitted to the hospital because of a
theophylline overdose. The patient was known to have severe bronchial
asthma that had required that she be hospitalized several times during
the 3 years preceding the present admission. She had been treated
chronically with prednisone; theophylline sustained-release tablets, 400
mg three times daily: and terbutaline by inhalation. The severity of her
asthma had increased in the last few weeks; she had been given a course
of trimethoprim/sulfamethoxazole, and the prednisone had been in-
creased to 20 mg three times daily. The patient had been depressed
because of family difficulties. The night of admission her granddaughter
found her lying on the floor, obtained a history ofa suicidal attempt, and
took her to the Emergency Department of the St. Joseph Hospital,
Joliet, Illinois. By the time of her arrival at the hospital, the patient was
alert and cooperative; she stated that she had taken all the theophylline
tablets in her possession, presumably more than 60. and that she had
vomited several times during the preceding hour.
Physical examination showed an obese woman who was complaining
of nausea. Arterial blood pressure was 124/62 mm Hg; respirations,
24/mm; and pulse rate, 142 beats/mm and regular. Auscultation of the
chest revealed scattered rales. Serum creatinine was 0.9 mg/dl. The
plasma theophylline level was 56 rg/ml. The patient was given activated
charcoal followed by magnesium citrate. During the next few hours she
remained hemodynamically stable and did not demonstrate evidence of
neuromuscular hyperexcitability or seizures, but an electrocardiogram
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showed persistent tachycardia complicated by multiple premature
ventricular contractions and runs of paroxysmal supraventricular
tachycardia. A theophylline level repeated several hours after admis-
sion was 60.7 rg/ml. A catheter was inserted into the right subclavian
artery, and hemoperfusion was carried out for 4 hours, using 2 AluKart
cartridges for 2 hours each. Table I charts blood flow rate through the
cartridge and theophylline plasma levels. At the end of hemoperfusion,
the pulse rate was 95 beats/mm, and the electrocardiogram showed
sinus rhythm. The theophylline level was 22.0 zg/ml one hour after the
end of hemoperfusion, and 8.8 jzg/ml 12 hours later. No changes in
blood pressure, no clinical evidence of bleeding, and no detectable
decrease in platelet count were observed.
Discussion
DR. SERAFINO GAREL.LA (Associate Chairman, Department
of Medicine, Michael Reese Hospital and Medical Center, and
Professor of Medicine, University of Chicago Pritzker School
of Medicine, Chicago, Illinois): Few encounters between phy-
sician and patient manifest the drama that attends the clinical
presentation of the poisoned victim. Patients, often young and
free of all physical marks of chronic disease, are brought to the
Emergency Room and found to be comatose, severely hypo-
tensive, and hypoxemic. Generalized convulsions and complex
cardiac arrhythmias sometimes develop, and the patient's ar-
rival is often heralded or followed by the appearance of several
distraught family members, who add to the confusion of the
scene, often giving contrasting and puzzling accounts of the
events surrounding the discovery of the poisoned patient. The
confusion is soon compounded by efforts at securing an open
airway, supplying additional oxygen, establishing access to the
circulation, and emptying the gastrointestinal tract of its con-
tents. All this tumult is played out in the context of ambivalence
among the staff, because few patients generate as much com-
passion mixed with anger as do the victims of self-poisoning [1].
The treatment of the poisoned patient traditionally has been
based on three main approaches: removal of the offending
agent, administration of antidotes, and use of supportive,
nonspecific therapy. Of these, the third may seem the least
appealing, perhaps because it has a connotation of passivity
that is out of keeping with the intensity of the events. By
contrast, the desire to carry out a spectacular and potentially
lifesaving rescue has resulted in attempts at developing a
variety of specific or universal antidotes, and in techniques
designed to accelerate the elimination of the poison. Unfortu-
nately, with relatively few exceptions (one of which might be
exemplified by today's patient), these attempts generally do not
produce the desired effect [2].
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Table 1. Hemoperfusion over 4 hours in the patient presented
Time
(minutes)
Blood
flow
rate
(mi/mm)
Theophylline plasma
levels (gIml)
Inlet Outlet
0 60.7
60 200 50.2 6.7
120 200 41.2 2.2
180 200 30.0 2.2
240 200 22.4 2.5
Reliance on antidotes can be traced back to the very origins
of medicine: magic formulae and incantations, charms, and
sacrifices were used in an effort to effect a cure in all sorts of
ailments, including poisonings, real or imaginary. In more
modern times, drugs that had a pharmacologic effect opposite to
that of the intoxicating agent were widely employed. The
administration of analeptic agents such as picrotoxin to coun-
teract barbiturate or sedative overdose is a classic example [3].
More recently, the use of technologically advanced processes
has produced effective antidotes. Representative of this new
breed of antidotes are the opiate antagonists, N-acetylcysteine
for acetaminophen intoxication [4], and anti-digitalis antibodies
[5].
Techniques developed for accelerating the elimination of
toxins from the body, either before the poison has been
absorbed from the gut or after it has entered the blood stream
and reached its target organs, have been numerous. Some of
these techniques are generally recognized as useful, at least
when used with the appropriate caution, and are employed
routinely. Emptying the gastrointestinal tract (through the
induction of emesis or by means of gastric lavage), administra-
tion of cathartics, and binding non-absorbed drug (through the
administration of activated charcoal) are often used [6—9] de-
spite some question as to the balance between their risks and
benefits [10]. Another time-honored approach intended to speed
up elimination of absorbed drugs is the induction of a brisk
diuresis coupled with manipulation of the urinary pH which, in
appropriately selected poisonings, results in "ionic trapping" of
the offending agent in the urine and thus in decreased renal
tubular reabsorption [11]. This technique has its own pitfalls
(excessive volume expansion and induction of systemic acid-
base and electrolyte disturbances) and requires adequate renal
function; in addition, its effectiveness is limited to only a few
specific intoxicants (alkaline diuresis enhances the elimination
of salicylates and long-acting barbiturates; acid diuresis in-
creases that of phencyclidine). Lastly, methods of drug removal
based on recently developed, sophisticated techniques that are
capable of extracting drugs from the blood stream, such as
dialysis and hemoperfusion, have attracted the attention of all
physicians who care for poisoned patients. Peritoneal dialysis is
now generally recognized to be only an adjunct to therapy in
special cases. Evaluation of continuous arteriovenous hemofil-
tration or hemodiafiltration for the treatment of some unusual
intoxications with poisons with tight tissue binding has just
begun. Hemodialysis, after a decade of intensive use and study,
is now acknowledged to be effective for only a handful of
situations. However, hemoperfusion, which has been proposed
as capable of extracting most offending drugs with exceptional
effectiveness, enjoys a persistent popularity. Its esteem is
confirmed not only by the number of publications reporting its
favorable effects, but also by the number of hemoperfusion
cartridges produced and sold yearly by the three United States
manufacturers or distributors. An informal telephone survey
revealed that this number reached several thousand units in
1986. Yet, I believe that a proper analysis of the evidence
published to date will show that the emphasis on extracorporeal
methods of treatment is largely misplaced, and that hemoperfu-
sion and hemodialysis have been shown to be effective in a
notably restricted number of intoxications.
In the course of this discussion I will review the epidemiology
of poisoning, the mode of action of hemodialysis and hemoper-
fusion in the removal of poisons, the differences between these
two techniques, and the pharmacologic concepts and empiric
data that can be used to either recommend or reject the
application of either procedure. I then will analyze in some
detail the treatment of those intoxications for which substantive
evidence exists that hemodialysis or hemoperfusion is indi-
cated. Finally, I will propose guidelines for the use of extracor-
poreal techniques in the treatment of poisoning.
The epidemiology of poisoning
Assembling an accurate representation of the epidemiology
of poisoning is difficult, because various agencies and organi-
zations survey different aspects of this issue. The National
Center for Health Statistics compiles data gathered from death
certificates. According to this source, there were 6247 deaths
due to poisoning in the United States in 1984; of these, 2981
were ascribed to suicide. Suicide is markedly underreported, so
these data undoubtedly are a minimum figure. Furthermore,
this information is not usable in a clinical context, because the
data represent a tabulation of all people who died as a conse-
quence of poisoning, most of whom were found dead and had
not come in contact with a physician [2, 12]. Thus, whereas
mortality statistics are extremely important from a public
health-preventive medicine viewpoint, they do not shed light on
the clinical consequences of poisoning in patients being cared
for by physicians. The latter perspective, however, is supplied
by the annual report of the American Association of Poison
Control Centers for 1985, which provides a fascinating, albeit
incomplete, picture of the causes, circumstances, and conse-
quences of poisoning in the United States [13]. The report was
compiled utilizing data submitted by 56 poison control centers,
Because the reporting centers were geographically widely dis-
tributed and encompassed a population base of 113.6 million
people [13], it is probable that the data reflect national trends.
Figure 1 shows that accidents account for almost 90% of
poisonings; suicidal intent accounts for about 8%; and a thera-
peutic mishap is responsible only for about 1%. Not surpris-
ingly, the severity of the clinical consequences is much greater
in the intentional cases, which indeed account for most of the
deaths. But even in patients with purposeful overdose, and
consequently with the highest risk, it must be noted that the
likelihood of developing a 'major effect" (defined in the report
as a consequence severe enough to require hospitalization) is
only about 3%, and that death occurs in approximately 10% of
the group that requires hospitalization. I also should note that
even though the poison control centers that collaborated on the
1985 annual report serve a population base equivalent to almost
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Total number of reported poison exposures:
900,513
Accidental Intentional Adverse reaction
809.817
(89.9%>
73,781
(8.2%)
11,912
(1.3%)
1232
(0.15%)
2185
(2.96%)
—
62
(0.5%l
64
(0.008%)
247
(0.33%)
6
(0.05%)
Fig. 1. Circu,ns lances and consequences fpoisonings. Data derived
from the 1985 Annual Report of the American Association of Poison
Control Centers [13]. Note that although intentional exposures were
less than 10% of the total, they accounted for the largest number of fatal
cases. An accidental exposure has only a probability of 1:10,000 of
resulting in death, whereas the probability is 3:1000 in cases of
intentional exposure. The likelihood of causing a "major effect"
(defined as a potentially life-threatening complication, usually requiring
hospitalization) is similarly greater in intentional than in accidental
exposures.
one-half of that of the United States, the total number of deaths
reported is only about one-twentieth of that tabulated by the
National Center for Health Statistics. This discrepancy con-
firms that in most cases death due to poisoning occurs before
the patient reaches a hospital or physician.
Among the myriad toxic agents responsible for poisoning,
only relatively few cause lethal consequences regularly. These
agents must be identified, of course, so that aggressive and
potentially specific therapy can be employed. Table 2, also
derived from the 1985 Annual Report of the American Associ-
ation of Poison Control Centers, displays the categories of
intoxicants that resulted in lethal events. In 1985, 317 deaths
occurred in almost 250,000 exposures. The data reveal several
notable points. The mean frequency of a "major effect" was
only 1.4% for the entire group of poisons. After a "major
effect" had occurred, patients had a 12.2% overall probability
of dying; again, some poisons seemed to have much greater
propensity than others to result in lethal consequences. Not
unexpectedly, cyanide was the agent with the highest likelihood
of causing death if the intoxication was serious enough to have
resulted in a "major effect." In decreasing order of lethality by
category were gases (carbon monoxide), chemicals and heavy
metals, "street" drugs, cardiopulmonary drugs, agricultural
preparations (such as pesticides), analgesics, alcohols, antide-
pressants and, finally, sedative/hypnotics. Analgesics caused
the largest number of deaths.
Being aware of the poisons that are most commonly ingested,
those that are most likely to cause serious medical conse-
quences, and those that have the greatest probability of result-
ing in death has important clinical implications. Knowledge of
the pharmacokinetic properties and modes of action of these
agents will allow us to predict whether dialysis or hemoperfu-
sion is likely to be effective, and whether other modes of
treatment should be specifically employed.
Ilernodialysis and hemoperfusion: Basis jr their
use in poisoning
The notion that a method capable of purifying the blood and
of accelerating the elimination of circulating toxins ought to
Table 2. Poisons reported to cause lethal events"
Major
effectL Death" %d
Alcohols
Ethanol 303 26 8.6
Isopropanol 18 5 27.8
Methanol 20 3 15.0
Ethylene glycol 36 7 19.4
Chemicals/heavy metals
9* 5 55.6Cyanide
Toluene/xylene 13 3 23.1
Arsenic 16 3 18.8
Agricultural preparations
5 2 40.0Diquat/paraquat
Organophosphates 61 6 9.8
Gases
Carbon monoxide 60 24 40.0
Analgesics
Aspirin 176 28 15.9
Acetaminophen 368 29 7.9
Propoxyphene 26* 5 19.2
Other/combination/unknown 78 25 32.1
Antidepressants
Cyclic antidepressants 618* 75 12.1
Lithium 51* 7 13.7
Other 201* 8 4.0
Cardiopulmonary drugs
77 Il 14.3Aminophylline/theophylline
Cardiac glycosides 21 4 19.0
Other (antiarrhythmics, /3-blockers, etc.) 110 17 15.5
Barbiturates 182* 9 4.9
Benzodiazepines 315 18 5.7
Gluthethimide 33 7 21.2
Phenothiazines 150 22 14.7
Other 102 6 5.9
Stimulants/' 'street drugs"
50 6 12.0Amphetamines
Cocaine 57* 18 31.6
Heroin 30* 8 26.7
Other 95 12 12.6
Total 3281 399 12.2
' Data from the 1985 Annual Report of the American Association of
Poison Control Centers [131.b Number of intoxications resulting in potentially life-threatening
medical complications and/or in permanent disability. The asterisk
identifies those agents that had a >3% likelihood of causing a "major
effect."
Number of deaths for each intoxicant. The cumulative number is
greater than that of the total number of deaths because more than one
intoxicant was identified in several cases.
d Percentage of patients with a "major" medical complication who
died.
improve prognosis in poisoned patients is intrinsically appeal-
ing. During hemodialysis or hemoperfusion, up to 400 ml of
blood per minute can circulate through the extracorporeal
circuit. The potential therefore exists that the same volume of
blood can be cleansed in that time. Hemodialysis is less
effective than is hemoperfusion for the majority of poisons
because the necessity of preventing the leakage of blood
components into the large fluid volume of the dialysate (while
withstanding a substantial hydrostatic pressure gradient) dic-
tates that dialysis membranes must have a relatively low
porosity and great thickness. Furthermore, the total surface of
the dialyzing membrane has an upper limit ofjust a few square
meters. By contrast, hemoperfusion cartridges are character-
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Table 3. Hemoperfusion devices available commercially in the United States
Adsorbent Coating
Manufacturer Device Composition surface (m2) thickness
Gambro Adsorba 300C 300 g of activated charcoal; cellulose
coating
300,000 3—5/.l.
Clarke R & D Biocompatible hemoperfusion
system
Activated carbon, available in 3 sizes.a
Not sterilized; heparin-hydrogel
coating.
2 2
Erika HemoKart Activated charcoal, available in 2 sizes
(65 and 155 g);h cellulose nitrate
coating.
85,000 or 200,000 <0.05k
a Clark Research & Development does not release information regarding amount of sorbent in its cartridges, mean thickness of coating, or
adsorbent surface, because of concerns about "the potentially misleading nature of this information." The Clark cartridge contains carbon rather
than charcoal; it is produced by synthesis from petroleum distillates.
b A third cartridge, AluKart, is also available; it is marketed primarily for the treatment of aluminum or iron overload in patients on chronic
dialysis, after administration of a chelating agent.
ized by ultrathin membranes of high porosity and extensive
surface area.
The principle of hemoperfusion is based on circulating blood
coming in direct contact with substances capable of adsorbing
toxins. The use of anionic exchange resins was first proposed
for the removal of uremic toxins in 1948 [14], and for the
extraction of exogenous poisons in 1958 [15]. It was soon
realized, however, that these resins caused an unacceptably
high rate of side effects (for example, hemolysis, severe throm-
bocytopenia, pyrogenic reactions), and it was not until acti-
vated charcoal was introduced as a sorbent [16] that the method
became clinically applicable (even though thrombocytopenia
and microembolism of particulate matter remained a major
concern). The frequency and severity of these complications
was substantially lowered only with the development of the
technique of microencapsulation [17]. By coating the sorbent
particles, it became possible to manufacture hemoperfusion
devices that contained either charcoal, or a nonionic polysty-
rene resin said to be more active than charcoal in the adsorption
of lipophilic poisons [18], in the form of microscopic granules
encased by a porous membrane.
The membrane coating in hemoperfusion devices can be
much thinner than that in hemodialysis equipment because it
need not withstand a hydrostatic pressure difference and be-
cause its function is simply that of encasing the particulate
material contained in the hemoperfusion column. The coating
thus prevents embolism and contact between the sorbent and
the formed blood elements. Charcoal, a product of distillation
of a variety of organic materials, can adsorb nonspecifically a
large number of substances [19]. Because its adsorbing capacity
depends to a large extent on the mean size of the granules and
their porosity, the charcoal is "activated" by processing it by
physical or chemical means such as exposure to steam, carbon
dioxide, or zinc chloride. When the charcoal granules are
activated, their diameter varies between 4 mx and more than
100 m [17]. The total adsorbent surface area of 100 g of this
substance reaches several thousand square meters. Table 3
describes some important characteristics of the hemoperfusion
devices commercially available in the United States. Resin
cartridges are no longer available, presumably because they
offer only marginal advantages over charcoal in the extraction
of lipid-soluble poisons and have a more limited range of
applicability.
The use of dialysis to treat poisoning, an application intro-
duced by Doolan [20] and championed by Schreiner [21] in the
1950s, gained wide acceptance in the l960s and early l970s. By
1972, poisonings due to practically all known toxic agents were
considered potentially treatable by dialysis [221. It is now clear,
however, that the indications for the use of hemodialysis are
limited to the treatment of intoxications due to drugs and
poisons that have a relatively small volume of distribution—
thus reaching plasma concentrations high enough to establish a
sufficient gradient—and that, in addition, have a low molecular
weight and are not markedly protein bound. Practically speak-
ing, these requirements limit the effectiveness of hemodialysis
to intoxications due to alcohols, salicylates, lithium, and
theophylline. Hemodialysis is also indicated in patients who
have renal failure or profound electrolyte or acid-base distur-
bances. By contrast, several theoretical arguments can be
adduced suggesting that hemoperfusion should be much more
versatile than hemodialysis and thus applicable to a large
variety of intoxicants. Because of the thinness and porosity of
the membrane that coats the sorbent microgranules, and be-
cause of the avidity with which charcoal can adsorb a wide
variety of substances, the passage of blood through a hemoper-
fusion cartridge results in almost complete removal of most
intoxicants. Of the drugs listed in Table 2, only heavy metals,
carbon monoxide, and some "street" drugs are not candidates
for hemoperfusion. Even drugs bound to circulating proteins or
lipids can be extracted almost completely in one pass. Unless
the binding is irreversible, an equilibrium exists between the
free and the bound fractions of the drug. Removal of the free
portion in the topmost layers of the sorbent results in liberation
of more free drug than can be adsorbed by the successive
layers, so that the blood exiting from the column is almost
completely cleansed. By measuring the concentration of a given
drug in the blood just before the blood enters and as it exits the
hemoperfusion cartridge, one can easily calculate the extraction
ratio of the drug with the formula (A-V)/A, where A is the
concentration of the drug in the inlet to the hemoperfusion
cartridge, and V the concentration at the outlet; a ratio of 1.0
signifies complete extraction of the drug in one pass. By
knowing the concurrent plasma flow rate through the cartridge,
one can calculate the clearance rate (flow rate x extraction
ratio). Table 4 lists the extraction ratios and clearance rates of
several drugs attained with charcoal or resin hemoperfusion.
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These data show beyond question that hemoperfusion is ex-
traordinarily efficient in extracting a wide variety of poisons
from the circulating blood [23—251. Apparently confirming these
data, the literature contains innumerable reports of patients
who appeared to be deathly ill when first seen by a physician,
and who seemed to recover almost miraculously after a few
minutes, or at most a few hours, of hemoperfusion. Martin et al
found charcoal hemoperfusion "a simple, safe and effective
method of treating severe poisoning due to glutethimide and
short acting barbiturates" [26]. This group also found hemoper-
fusion effective in removing paraquat [261. Volans and cowork-
ers confirmed these findings and concluded that the technique
was safe and useful. In their words, "It would . . . seem
reasonable for this technique to be generally available provided
that it is carried out by specialist, regional units with adequate
laboratory facilities" [27]. Trafford and colleagues reported on
11 patients with severe poisoning due to a variety of sedatives
and tricyclic antidepressants; all but one patient showed rapid
clinical recovery, and plasma clearance rates of the drugs
varied between 76 mI/mm and 300 mI/mm [28]. Haapanen
treated 48 patients; in 23 the responsible drugs were barbitu-
rates or meprobamate, and . . . with one exception they all
showed remarkable improvement during the treatment" [291.
Patients with salicylate, paracetamol, quinidine, propranolol, or
mushroom intoxication also appeared to benefit greatly [29].
In view of the data on extraction ratios and clearance rates,
and the enthusiastic reports of clinical effectiveness, it is not
surprising that hemoperfusion has been recommended for pa-
tients who are severely intoxicated, especially if they fail to
improve with the usual supportive measures [23, 24]. This
recommendation seemingly has been heeded, if the sales data of
hemoperfusion devices that I alluded to earlier reflect actual
usage.
Theoretical considerations on the elf 'ctiveness
of hemopeifusion
Despite the very high extraction ratios and clearance rates
that can be obtained with hemoperfusion,* theoretical and
clinical factors must be taken into consideration before
hemoperfusion is generally accepted as treatment for intoxica-
tions. The theoretical considerations focus on the fact that
many common intoxicants have pharmacokinetic properties
which predict that cleansing of the circulating blood, no matter
how effectively done, will not result in a clinically detectable
beneficial effect. In fact, these considerations reveal that evi-
dence derived only from extraction ratios and clearance data
can be misleading.
After absorption, the distribution of each drug in the various
body compartments is highly individualized and depends on
*Note that if the extraction ratio remains constant with changing blood
flow rates, the clearance rate will be determined by the blood flow rate
through the hemoperfusion device. Extraction ratios in practice are not
completely stable, and tend to decrease with increasing flow rates and
with the passage of time (as the sorbent contained in the cartridge
becomes saturated). However, at least at the beginning of the proce-
dure, clearance tends to change in parallel with changes in blood flow
rate: this is responsible for the extreme variability of the figures
reported in the literature, of which the data shown in Table 4 are only
representative examples.
Table 4. Drug extraction ratios in hemoperfusion'
Drug
Charcoal
hemoperfusion
Resin
hemoperfusion
Salicylate 0.5 —
Digoxin 0.3—0.6 0.4
Ethchlorvynol 0.7 1.0
Gluthethimide 0.65 0.8
Methaqualone 0.5—1.0 1.0
Phenobarbital 0.5 0.85
Theophylline 0.7 0.75
a Data modified from Ref. 23. Data are calculated for blood flow rates
of 200 mI/mm, at the midpoint of the procedure.
several factors, which include the molecular weight of the drug,
its ionization at the prevailing pH of body fluids, the presence or
absence of specific transport mechanisms, its lipid solubility,
the degree of protein binding, and the apparent volume of
distribution [30, 31]. The interplay of these factors determines
not only the total amount of the drug that is present in various
body tissues (such as fat, muscle, parenchymatous organs) and
present in the extracellular fluid and plasma, but also dictates
how easily the drug moves from one to another compartment,
and how accessible it is to extracorporeal depuration.
A few examples will make the importance of these issues
clear. Let us consider first the tricyclic aritidepressants that as
a group were responsible for the second largest number of
deaths described in the 1985 Annual Report of the American
Association of Poison Control Centers (Table 2). This class of
drugs has an extraction ratio that approaches 1.0, and a plasma
clearance rate that can be as high as several hundred mi/mm
with resin hemoperfusion [32, 33]. In keeping with these data,
hemoperfusion first was reported to be very effective in the
treatment of tricyclic overdose [25, 28, 32, 341. However,
tricyclic antidepressants have a very high lipid/water partition
coefficient [33]; very little of the total absorbed dose remains
confined to the plasma. The apparent volume of distribution
(the volume of plasma that would be necessary to dilute the
drug to the concentration observed in vivo after equilibration)
has been reported to be greater than 40 liters/kg body weight
[351. If a 60 kg patient ingests 100 tablets of a tricyclic agent,
each containing 25 mg, for a total dose of 2500 mg, after
equilibration into an apparent volume of distribution equivalent
to 40 liters/kg body weight, the plasma concentration of the
drug will be about 1.0 tg/ml, clearly a life-threatening level
(therapeutic levels for this class of drugs are in the range of 0.1
rg/ml). Let us say that this patient undergoes resin hemoperfu-
sion for 4 hours, with a blood flow rate of 350 mI/mm, which is
equivalent to a plasma flow rate of about 200 mI/mm. Even
though the circulating drug can be 95% bound to plasma
proteins, because of the extraordinary efficiency of resin
hemoperfusion, the extraction ratio may be 1.0. At this flow
rate and extraction ratio, the clearance will then be 200 mI/mm.
Therefore, 200 xg will be removed per minute, for a total
removal of 48 mg over 4 hours. Despite the efficiency of the
procedure in depurating the plasma, the total-body drug burden
therefore would have been decreased by less than 2%!
Another relatively common intoxicant that behaves similarly
to the tricyclic antidepressants is digoxin. This drug has a high
specific binding to muscle fibers as well as a high binding ratio
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to circulating proteins. Digoxin's apparent volume of distribu-
tion is about 10 liters/kg body weight [35, 361; furthermore, it is
not easily released from its cardiac binding sites, where it exerts
its toxicity [361. Because of these factors and because of its
poor therapeutic/toxic ratio, digoxin can cause fatal poisoning
at very low plasma levels; these low levels render hemoperfu-
sion futile. Severe toxicity with digoxin can occur at plasma
concentrations as low as 10 ng/ml. Complete removal of circu-
lating digoxin through a hemoperfusion device with a plasma
flow rate of 200 mI/mm would result in the removal of 2000
ng/min, or only 480 in 4 hours, hardly a clinically notable
amount. In view of these considerations, it is indeed fortunate
that better treatment modalities have become available for this
toxin [5].
Whereas a large apparent volume of distribution—and con-
sequently a low plasma concentration relative to the total-body
burden of the intoxicant—implies that methods of plasma
depuration likely will be ineffective, a low apparent volume of
distribution by no means ensures success with these methods of
treatment. A tight binding of the offending agent to its target
tissue may well cause a failure of hemoperfusion, even when
the drug has a relatively low apparent volume of distribution.
This possibility is exemplified by paraquat, a widely used
herbicide that causes severe acute (local ulcerations, cardiac,
hepatic and renal failure, seizures, and death) and subacute
(pulmonary edema progressing to pulmonary fibrosis) toxicity
through its release of superoxide [37]. This poison is highly
polar and hydrophilic; these characterisitics suggest that char-
coal hemoperfusion should be more efficient than resin
hemoperfusion. Indeed, charcoal hemoperfusion promptly re-
sults in complete elimination of the circulating paraquat. Un-
fortunately, because of the tenacious tissue binding of the toxin,
the procedure is ineffective in improving prognosis and removes
only minuscule amounts of the poison [33, 38, 391. Despite
opinions to the contrary [37], it appears extremely unlikely that
the prognosis in paraquat intoxication can be markedly im-
proved by hemoperfusion. Other drugs share this property of
tight tissue binding, although to a lesser extent than paraquat.
These include some lipid-soluble hypnotics, mainly gluteth-
imide and short-acting barbiturates; their binding to lipids
prevents their release into the circulation and markedly hinders
their removal.
On the basis of these observations, it is clear that a high
extraction ratio or a high clearance rate for a given toxin are
merely necessary prerequisites to suggest the potential effec-
tiveness of hemoperfusion; they are, however, by no means
sufficient evidence that hemoperfusion (or any other method of
extracorporeal detoxification of blood) will be clinically effica-
cious. An improved understanding of the pharmacokinetic
concepts I have outlined here has forced a reevaluation of the
indications for the use of hemoperfusion. For example, despite
the initial enthusiastic reports [25, 28, 32, 34], most investiga-
tors generally agree that hemoperfusion is not indicated in the
current treatment of tricyclic antidepressant overdose [29, 40].
How do we reconcile the evidence that drugs such as tricyclic
antidepressants cannot be effectively removed by hemoperfu-
sion (because of their high volume of distribution and lipid
binding) with the many clinical observations of a prompt and
dramatic response to hemofiltration? Whereas we might be
tempted to ascribe such unexpectedly favorable reports to the
imprecision of clinical observations, an alternate interpretation
can be advanced. According to this hypothesis, the removal of
even a small fraction of the total-body burden of a drug might
result in substantial clinical improvement if the lowering of the
plasma level of free drug results in prompt movement of the
drug from the functionally important toxic sites to the plasma
[361. In the case of tricyclic antidepressants, toxic activity is
exerted in the central nervous system and in the myocardium,
both highly vascularized tissues, whereas the majority of the
drug may be "locked into" poorly perfused fat deposits. In
theory, hemoperfusion might remove a small amount of the
poison from the plasma; this quantity might be promptly
replaced by drug loosely bound to myocardium and to brain.
The patient at this point could become alert, possibly could
provide important historic details, and arrhythmias might abate.
Following cessation of hemoperfusion, the portion of the drug
that was more tightly bound to lipids might, according to this
hypothesis, be released. Thus, the potential exists for a toxicity
rebound" or, if the rate of release were slow enough, an
equilibrium with the total rate of elimination or metabolism. In
the latter case, hemoperfusion would be clinically effective
despite having caused only a minuscule reduction in total-body
burden of the poison, because of preferential removal of the
poison from the "toxic compartment" [36].
Empiric observations on the clinical effectii'ness
of he,noperfi,sion
Because knowledge of the pharmacologic behavior of each
drug might not permit us to reach a definitive answer in all
cases, it is apparent that the question Does hemoperfusion
markedly improve prognosis or decrease morbidity in exoge-
nous poisonings?" must be answered at this time through
detailed clinical observations. Unfortunately, only three clinical
studies have compared hemoperfusion with supportive treat-
ment. All these studies suffer from severe limitations and reach
debatable conclusions. Volans et al reported on 21 patients
treated with charcoal hemoperfusion for severe intoxication
due mostly to a variety of hypnotics [27]. The patients were
retrospectively compared with 36 patients treated with conserv-
ative means only. Duration of coma appeared to be shortened
by hemoperfusion. Five deaths occurred in each group; the
mortality rate in the hemoperfused group was higher than in the
"control" group (24% versus 14%). Yet the authors concluded
that The treatment was free from major side effects and in the
patients who survived it appeared to make a real contribution
towards recovery." The higher mortality rate in the treated
group was attributed to the implied greater severity of intoxi-
cation in these patients (of whom 4 had had a cardiorespiratory
arrest before the onset of hemoperfusion). Hampel and cowork-
ers [41] reported 70 patients with poisoning due to hypnotics
who were believed to be candidates for hemoperfusion because
of the severity of their clinical manifestations and plasma drug
levels [27]. Seventeen were hemoperfused; the method of
selection was not stated. One patient (6%) in this group died. Of
the control group, 11 patients (2 1%) died. Bismuth et a! ob-
served a mortality rate of 13% in 60 patients who were
hemoperfused [42]. This rate was much higher than the average
rate of 2.5% that they had found in nonhemoperfused patients.
The authors believed, however, that the method of selection for
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Number of patients with "severe" intoxication (%)
Sex: male/female
Age range (years)
Staging of coma [44]
Stage IV
Stage 111
Stage Ii and I
Clinical complications at admission
Requirement for intubation and ventilatory support
Hypotension (<90 mm Hg)
Aspiration, with or without pneumonia
Convulsions
Hypo- or hyperthermia
Intoxicating agents
Tricyclic antidepressants and phenothiazines
Barbiturates
Benzodiazepines
Ethchlorvynol
Salicylates
Glutethimide
Other
Unidentified
Multiple ingestions
146 (24.3)
49/97
1.5—85
107
29
10
99
42
33
8
19
hemoperfusion might have singled out the more severely poi-
soned patients.
The incomplete and confusing information provided by these
three studies [27, 41, 42] makes it clear that an extensive,
properly designed and executed, blinded and controlled study is
necessary if a satisfactory answer is to be reached regarding
which patients should be hemoperfused, for which drugs, and at
what point in their clinical course. Such a study has not been
performed; indeed, given the low percentage of intoxications
that are severe enough to warrant hemoperfusion, the large
number of poisons with their different characteristics, and the
myriad diverse clinical conditions that can affect the course of
the poisoned patient, such a comprehensive study probably is
not feasible. Some data are available, however: although falling
short of providing the definitive information that a controlled
study would provide, this information can be used to guide the
clinician faced with the immediate need for reaching a prompt
decision of whether to hemoperfuse. In collaboration with J.
Lorch, I evaluated the presentation, clinical course, frequency
of complications, and prognosis of all poisoned patients admit-
ted to the Rhode Island Hospital over a 5-year period [2, 12].
This study, in which no hemodialysis or hemoperfusion was
used, provides a reasonably complete depiction of the natural
history of poisoning that is treated conservatively. Six hundred
consecutive admissions were analyzed; all poisonings were
toxicologically confirmed by gas chromatography-mass spec-
trometry [43]. Of the 600, 146 patients (24%) fulfilled conven-
tional criteria for consideration for hemoperfusion [22]. Clinical
data on these severely poisoned patients are shown in Table 5.
These patients' clinical course was analyzed with two specific
purposes: first, to determine whether we could decide early
after admission which patients should be considered for
hemoperfusion; the second, to find out whether the frequency
of development or of resolution of complications and the
mortality rate are likely to be influenced by hemoperfusion. The
answer to both questions was no.
Is it possible to identify patients, when they are first admitted
to the hospital, whose intoxication is severe enough to warrant
hemoperfi4sion? One of the major aims of any procedure used to
diminish the body burden of an intoxicant is to shorten the
period of exposure to the toxic action of the poison, and thus
presumably to decrease the length of coma and the likelihood of
complications [22, 23, 45]. It is therefore desirable to identify
the patients who are the most likely to benefit from an aggres-
sive approach. Because the a priori probability of mortality is
only in the range of 1% to 2% for all patients admitted to the
hospital for drug intoxication [46—49], guidelines must be devel-
oped to narrow down the number of candidates for hemoperfu-
sion. Reliance on serum drug levels for this purpose is not
warranted: with few exceptions (for example, the alcohols,
ethylene glycol, acetaminophen, theophylline), serum drug
levels do not correlate well with degree of toxicity, prognosis,
or duration of coma [50—521. Thus the selection guidelines must
be based on clinical criteria. Reasoning that the length of stay in
the intensive care unit is an objective criterion of the severity of
intoxication, we studied the correlation between this parameter
and the number of complications arising within 4 hours of
presentation to the hospital in each of the 146 patients just
mentioned. Complications included hypotension, arrhythmias,
hypo- or hyperthermia, stage IV coma, seizures, need for
intubation and ventilatory support, and aspiration. Figure 2
displays our observations: 80% of all patients with 4 or more
complications on admission stayed in the I.C.U. for more than
48 hours; 80% with 3 or fewer complications stayed less than 48
hours; but we found no definite correlation between the number
of complications present on admission and the length of stay in
the I.C.U. Some patients with three or more complications
were clinically stable and were discharged within 24 to 48
hours, whereas some who had an apparently mild intoxication
required I.C.U. care for several days. This observation will not
surprise physicians familiar with drug intoxication. Patients
Table 5. Pertinent clinical characteristics of 600 consecutive patients
admitted to the Rhode Island Hospital with a toxicologically
confirmed diagnosis of poisoning
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Fig. 3. Time of detection (left panel) ond time of resolution (right panel)
of complications in 146 patients with severe' intoxication. From
Controversies in Nephrology 1980. edited by Schreiner GE et al, New
York, Masson Publishing, © Division of Nephrology, Georgetown
University, Washington D.C.
who appear deathly ill at admission, with convulsions, apnea,
hypotension, and arrhythmias, can stabilize rapidly and be
arousable within a few hours; others who seem to have a minor
intoxication can have a complicated course. The data reveal
that clinical criteria are not sufficiently sharp to allow identifi-
cation at admission of patients who need hemoperfusion. To be
assured that all patients who might benefit from hemoperfusion
receive it, then, one would have to take the unreasonable
viewpoint that all patients with "serious" intoxications must be
hemoperfuscd.
Is hemoperfusion likely to influence the frequency of compli-
cations or the mortality rate? To answer this question, we
analyzed the time of detection and the time of resolution of each
complication for each of the 146 patients with 'severe" poi-
soning [23, 241. The results are displayed in Figure 3: 94% of all
complications of intoxication were present within 4 hours of the
time the patient presented to the hospital; 5% appeared between
4 and 24 hours, and only 1% developed at least 24 hours after
admission. The resolution of these complications was surpris-
ingly rapid as well: 76% resolved within 24 hours, and an
additional 14% within 48 hours. The most immediately life-
threatening complications (hypotension, arrhythmias, vcntila-
tory failure) were also those that tended to resolve first;
aspiration pneumonitis obviously tended to persist for longer
periods. This information conforms with previous reports indi-
cating that the likelihood of serious morbidity in intoxications is
greatest in the initial hours, when arrhythmias and hemody-
namic and ventilatory failure—if not aggressively counter-
acted—can easily result in death [2, 53, 54]. Complications that
appear late or persist beyond 48 hours are likely to represent
not the persistence of the toxic action of the drug itself, but the
continued presence of a complication that developed during the
initial period of intoxication: aspiration pneumonia, other infec-
tious problems (such as sepsis secondary to bladder catheter-
ization or to vascular carmulation), or the aftermath of
cardiorespiratory arrest.
In our study, 7 deaths occurred among the 600 patients,
accounting for an overall mortality rate of 1%. Calculated only
for the cohort of patients with 'severe" intoxication, the
mortality rate was 5%. In 5 of the 7 deaths, the patients had a
severe, protracted cardiorespiratory arrest either while being
transported to the hospital or on arrival at the emergency
department; intoxicating agents were isopropyl alcohol in one,
and mixtures of barbiturates, tricyclic antidepressants, and
propoxyphene in 4. The remaining 2 patients had taken cyto-
plasmic poisons, thallium and acetaminophen, which are not
amenable to hemoperfusion or hemodialysis 155—57]. It is of
interest that a search of the records of the Medical Examiner for
the State of Rhode Island (a small state with centralized record
keeping) reveals that only about 25% of patients who die of
poisoning are seen by physicians before they expire [21. 'I'his
information explains the discrepancy I noted between the total
number of deaths due to poisoning as compiled by the National
Center for Health Statistics and that tabulated by the American
Association of Poison Control Centers 1131.
I conclude from this information that clinical and biochemical
criteria for early identification of patients with the most severe
intoxications, who theoretically might benefit the most from
hemoperfusion, are inadequate. Most deaths from poisoning
occur before the patients reach medical attention or in the initial
phases of medical care, before time is available to institute
extracorporeal blood depuration. Even in the minority of pa-
tients who, despite having a life-threatening intoxication, re-
main alive for a period sufficient to allow hemoperfusion, severe
hypotension, hemodynamic instability, and arrhythmias can be
aggravated by or preclude hemoperfusion or hernodialysis. For
the time being at least, or until a controlled study becomes
available, we must conclude that for most common intoxi-
cants—and certainly for sedatives, hypnotics, and tricyclic
antidepressants—hemoperfusion and hernodial ysis are not ap-
propriate therapy [2, 12, 581.
Special cases: Intoxications that respond to hemoclialysis
and/or hemopcrfusion
On the basis of the pharmacodynamic concepts I have
discussed, it is not surprising to find that the intoxicants most
successfully removed by either hemodialysis or hemoperfusion
share a low apparent volume of distribution and molecular
weight, are only partially or not at all bound to plasma proteins,
and do not have important or tight tissue binding properties.
Furthermore several of these drugs, when taken in excessive
amounts, cause a clinical syndrome characterized by severe
acid-base disturbances, and the therapeutic use of hemodialysis
thus becomes all the more imperative. Table 6 lists the intoxi-
cants br which extracorporeal techniques of removal are
effective and potentially lifesaving. In this section 1 will not
describe in detail the clinical consequences of intoxication with
each of these agents; rather, 1 will attempt to keep the discus-
sion focused on the clinical aspects and pharmacologic proper-
ties of importance to the nephrologist trying to determine the
advisability of using exiracorporeal methods of depuration.
The alcohols. The most common intoxicant in this class of
drugs is ethanol. Ethanol causes severe chronic consequences
as well as a life-threatening acute toxic syndrome; however,
because this drug is rapidly metabolized and does not cause the
accumulation of toxic metabolites, neither hemodialysis nor
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Table 6. Pharmacologic characteristics of drugs that are substantially removed by extracorporeal techniques'
Intoxicant
Molecular
weight
Protein
binding
(%)
Vd
(LIkg)
Severe
toxic
levels Comments
Isopropyl alcohol 60 — 0.6 400 mg/dl Acetonemialacetonuria without hyperglycemia or acidemia. Osmolal gap":
17 mOsm per 100 mg/dl + 18 mOsm per 100 mg/dl of acetone.
Methyl alcohol 32 — 0.6 50 mg/dl "Double gap:" Metabolic acidosis with I anion gap due to formate accu-
mulation; and osmolal gap (31 mOsm per 100 mg/dl of methanol). Latent
period. Visual disturbances and papilledema.
Ethylene glycol 46 — 0.6 ?' Triphasic clinical picture. "Double gap:" Acidosis and anion gap due
to glycolic and lactic acid; and osmolal gap (16 mOsm/L per 100 mg/dl
Salicylate 138 5090" 0.2 800 g/ml
of ethylene glycol). Oxalate crystals in urine. J. ICa],,.
Persistent respiratory alkalosis; metabolic acidosis with I anion gap
(more common in children). Purple Phenistix reaction.
Lithium 7C 0.8 2.5 mEq/L Acute toxicity often superimposed on chronic side-effects (nephrogenic di-
abetes insipidus). Hemodialysis necessary in the presence of renal fail-
ure.
Theophylline 180 — 0.5 60 g/ml Cardiac arrhythmias and CNS toxicity prominent. Hemoperfusion pre-
ferred, but hemodialysis also efficacious.
a Vd refers to the apparent volume of distribution; severe toxic level refers to the plasma concentration of the intoxicant that often is lethal unless
aggressively treated.
The most common cause of an "osmolal gap" in clinical practice is ethanol intoxication, in which case the discrepancy between measured and
calculated osmoality is 22 mOsm/liter per 100 mg/dl of ethanol.
C There is no commonly accepted level of ethylene glycol that can be used as a guideline for aggressiveness of therapy. In view of the potential
seriousness of this poisoning, practically any positive level, if accompanied by symptoms of intoxication and especially by metabolic acidosis.
dictates the use of alkali, ethanol blockage of alcohol dehydrogenase, and hemodialysis.
d Protein binding is highest at low (therapeutic) plasma levels, and progressively lower with increasing (toxic) levels.
Molecular weight for lithium carbonate is 74.
hemoperfusion has a place in the treatment of acute ethanol
intoxication, and I will not discuss acute ethanol toxicity
further.
A clear, colorless, slightly bitter liquid, isopropyl alcohol
(isopropanol) can cause intoxication through ingestion or, in
infants, inhalation of vapors when used for fever sponging. It is
found in denatured alcohol, solvents and cements (used for
china, models, etc.), cleaning products, de-icers, and in highest
concentration in "rubbing alcohol." When taken by mouth, it is
readily absorbed by the stomach, where it can cause severe
gastritis with hemorrhage. The toxic dose is variable: 20 ml can
induce symptoms, but the lethal dose ranges from 150 to 240 ml
[59]. After absorption, isopropanol acts as a central nervous
system and myocardial depressant. It is approximately twice as
potent as ethyl alcohol in its toxic effect on the central nervous
system [59]. The plasma level usually considered life-threate-
ning is in the range of 400 mg/dl [61], but clinical signs and
symptoms (mainly hypotension) are a more reliable prognostic
indicator than is the plasma level [61].
Isopropyl alcohol undergoes oxidative metabolism through
the action of alcohol dehydrogenase; acetone is formed and
then predominantly excreted by the kidney (Fig. 4). This
metabolic process is slower than that for ethanol, and conse-
quently the duration of the intoxication can be considerable. In
contrast to methyl alcohol and ethylene glycol, the accumula-
tion in the plasma of the metabolic end-product of isopropanol
does not cause metabolic acidosis, but does result in aceto-
nemia and acetonuria. The diagnosis of isopropyl alcohol
intoxication should be suspected in any patient who becomes
comatose after a brief period of ataxia and lethargy. The breath
suggests acetone, and the nitroprusside reaction in the plasma
and urine is positive, but no hyperglycemia or glycosuria is
present. As in ethanol intoxication, which causes an "osmolal
gap" of 22 mOsm/liter for each 100 mg/dl, plasma osmolality is
higher than calculated osmolality: 100 mg/dl of isopropyl alco-
hol contributes approximately 17 mOsm/liter, and 100 mg/dl of
acetone increases osmolality by an additional 18 mOsm/liter*
[61]. Plasma bicarbonate concentration usually is not de-
pressed, and the anion gap usually is normal in isopropanol
intoxication, unless severe hypotension with tissue hypoxia and
lactic acidosis supervene.
Most patients with isopropyl alcohol intoxication survive
when treated with appropriate supportive measures [60, 611. In
the occasional patient with prolonged coma, hypotension, evi-
dence of myocardial depression or tachyarrhythmias, and
plasma levels greater than 400 mg/dl, hemodialysis should be
considered. Hemodialysis removes both isopropanol and ace-
tone efficiently, thus shortening the duration of coma and
potentially reversing the hemodynamic consequences of the
intoxication. The rate of removal of these two compounds is 40
to 50 times faster through dialysis than via renal excretion [63].
The presence of renal failure, either induced by hypotension or
due to preexistent renal disease, strengthens the indication for
hemodialysis. A spurious elevation in serum creatinine concen-
tration also can be a consequence of high levels of plasma
acetone [64].
A product of the distillation of wood, refined methyl alcohol
(methanol) is almost odorless. It is a widely used industrial
solvent and is found in de-icing solutions, carburetor fluid,
washing solutions, fuel for model engines, duplicator fluid, and
*Note that the "osmolal gap" is seen only when osmolality is measured
by freezing point depression. When it is measured by vapor pressure
osmometry, the osmolal gap may not be detected in any of the alcoholic
intoxications because of the volatility of these intoxicants [62].
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Fig. 4. Pathways of metabolism of the four alcohols that most coin-
monly cause intoxication. Alcohol dehydrogenase (bold arrow)is the
cytosolic enzyme that is responsible for the first oxidative step in all
four alcohols. Aldehyde dehydrogenase (star) a mitochondrial enzyme,
is responsible for the second oxidative step in ethanol, methanol, and
ethylene glycol. The products of metabolism that are responsible for
major toxic actions are enclosed in boxes. The question marks denote
metabolic steps where there is uncertainty about the specific enzyme(s)
involved and about the generation of NADHH. Note that oxalic acid
represents only a small fraction of the metabolites of ethylene glycol,
and that several additional metabolites are not shown in this figure.
"bootleg" liquor. This last source has caused epidemics of
methyl alcohol intoxication, which have been studied exten-
sively [65, 661. Methyl alcohol causes central nervous system
effects similar to those caused by ethanol; after 6 to 24 hours,
however, additional toxicity becomes evident. The clinical
picture is quite variable, but subjective visual changes accom-
panied by peripapillary edema and hyperemia of the optic discs,
metabolic acidosis with increased anion gap, and painful ab-
dominal crises probably due to pancreatitis [65] are the cardinal
manifestations.
The amount of methanol necessary to cause toxicity and
death is extremely variable: some patients are seriously affected
by the ingestion of a few milliliters of methanol, whereas others
survive ingestions of several hundred milliliters [60]. Like
isopropyl alcohol and ethylene glycol, methyl alcohol causes an
osmolal gap, the discrepancy between calculated and measured
osmolality being approximately 32 mOsm/liter for each 100
mg/dl increment in methanol concentration. The correlation
between the serum methanol level and the prognosis is poor [60,
67—69], probably because methyl alcohol per se does not act as
the toxic agent; rather, toxicity is due to its catabolic products.
By the time the correct diagnosis is suspected, a variable
fraction of methanol may be oxidized, yielding the toxic prod-
ucts formaldehyde and formic acid. It is probably the latter that
is primarily responsible for the metabolic acidosis, optic nerve
damage, and central nervous system and cardiac damage, The
degree of acidosis is a predictor of mortality [651, possibly
because it mainly reflects the concentration of formate [681.
Methanol is acted on by alcohol dehydrogenase; this reaction
results in the formation of formaldehyde (Fig. 4). The half-life of
this compound is only a few minutes; thus, no measurable
accumulation occurs. Formaldehyde is in turn oxidized to
formic acid by aldehyde dehydrogenase; the slower metabolism
of formate results in its accumulation, which may reach values
greater than 20 mEq/liter, and which accounts for the metabolic
acidosis with an increased anion gap. Because the affinity of
alcohol dehydrogenase for methanol is only approximately
one-tenth of its affinity for ethanol, therapy consists of the
administration of ethanol to retard the metabolism of methanol*
and of hemodialysis to eliminate methanol from the circulation.
In view of the extremely serious potential effects of this
intoxication, its latent period, and the poor correlation between
amount ingested and plasma levels with outcome, ethanol
administration and hemodialysis should be employed as soon as
a secure diagnosis is established, and immediately after appro-
priate measures for supporting ventilation and circulation (in-
cluding the acute administration of bicarbonate to reduce aci-
dosis) have been implemented. Ethanol can be given orally or
intravenously [67, 71]. A plasma level of ethanol of 100 mg/dl or
slightly higher is adequate to almost completely saturate alcohol
dehydrogenase [72]; this level can be achieved by the adminis-
tration of a loading dose of approximately 0.6 g/kg, and main-
tained by the administration of about 100 mg/kg/hr [67, 71].
These dosage regimens require frequent monitoring and adjust-
ment because the half-life of ethanol varies considerably. The
institution of hemodialysis increases the requirement of etha-
nol, which during dialysis must be given in greater amounts or
added to the dialysate at a concentration of 100 mg/dl. Hemo-
dialysis is best performed utilizing a bicarbonate bath, because
in the presence of severe acidosis the alkali requirement can be
massive.
In conjunction with the ethanol-induced blockade of the
action of alcohol dehydrogenase, hemodialysis is effective in
reducing the mortality rate and the permanent optic sequelae of
methanol poisoning [70, 73]. Dialysis not only accelerates the
elimination of the parent compound but also its toxic metabo-
lites [68, 74, 75] and corrects the metabolic acidosis. The
amount of methanol removed by hemodialysis depends on its
plasma concentration, the rate of blood flow through the
dialyzer, and the type of dialyzer employed. Using a 1.5 to 2.0
m2 dialyzer and a blood flow rate of 200 to 300 mI/mm, the
clearance rate is between 100 and 200 mI/mm. To gain a
quantitative insight regarding the effectiveness of hemodialysis
on methanol removal, it is instructive to recalculate the data
provided by McCoy and colleagues [67]: a 51 kg woman was
treated with a 6-hour hemodialysis. Her predialysis methanol
*The duration of the latent period between ingestion of methanol and
the development of evidence of intoxication due to the formation of its
metabolic products is most likely related not only to the amount
ingested, but also to the frequent concurrent ingestion of ethanol [70].
H20
NADH+H'
CH3—COOH
ACETATE
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level was 200 mg/dl, and the final concentration was 40 mg/dl.
Because the rate of decrease in plasma concentration during
dialysis was linear, the mean plasma level was 120 mg/dl.
Average blood flow through the dialyzer was 190 mI/mm. The
clearance rate through the dialyzer was 98 mI/mm, which
calculates to a total amount of 28 g of methanol removed during
6 hours of dialysis. Total-body burden of methanol at the onset
of dialysis was approximately 60 g (60% of body weight x
plasma methanol level); thus, dialysis decreased total-body
burden by about 50%. Even though some "rebound" due to
redistribution of methanol occurs after the termination of he-
modialysis [681, it is clear from these and other data [69, 70, 731
that hemodialysis can substantially decrease the total-body
burden of toxin and improve prognosis, especially if hemodial-
ysis is employed soon after ingestion, before irreversible con-
sequences have occurred [731.
Ethylene glycol, a colorless and odorless liquid with a sweet
taste, is ingested for its inebriating qualities. Widely used as a
solvent and as an antifreeze, it causes approximately 60 deaths
annually in the United States [76]. Like methanol, ethylene
glycol itself is not the direct cause of the major toxic conse-
quences of its ingestion; rather, these effects seem to be the
result of the action of its metabolites. The lethal dose is in the
range of 100 ml, but patients known to have ingested much
more have survived. The clinical syndrome resulting from
ethylene glycol poisoning is classically described as comprising
three phases [77—801. The first phase occurs within minutes of
ingestion and lasts for about 12 hours. It is characterized by
lethargy, agitation, and confusion, and it progresses to gener-
alized convulsions and coma. Metabolic acidosis, often severe,
with a correspondingly increased anion gap is common. Tetany
due to hypocalcemia occasionally is observed, and leukocytosis
and xanthochromia of the cerebrospinal fluid can occur. If the
patient survives this initial phase, hypertension, cardiac dila-
tion, and cardiopulmonary failure dominate the clinical picture
12 to 24 hours later. Finally, 24 to 72 hours after the ingestion,
renal failure develops; it is often accompanied by flank pain and
severe oliguria but is commonly reversible with proper support-
ive treatment [77, 79].
Although not completely understood, the major features of
the metabolic pathway of ethylene glycol have been described.
The first product of oxidation of ethylene glycol is glycoalde-
hyde, and this step is catalyzed by alcohol dehydrogenase (Fig.
4). Because this enzyme has a one-hundredfold greater affinity
for ethanol than for ethylene glycol, the administration of
ethanol is effective in delaying the metabolism of ethylene
glycol, increasing the fraction of the parent compound that is
excreted in the urine, and markedly diminishing the formation
of toxic breakdown products. In the absence of ethanol, glyco-
aldehyde is oxidized to glycolate. This compound is metabo-
lized to glyoxylic acid, which is then metabolized to a series of
compounds (glycine, oxalomalate, formate, etc., not shown in
Fig. 4). A proportionally small amount of oxalic acid is formed,
which gives rise to oxalate crystals in the urine, and which
might be responsible for the occasional development of hypo-
calcemia; oxalic acid is not, by itself, responsible for the acute
renal failure, however [79]. The degrees of toxicity and meta-
bolic acidosis correlate best with the extent of accumulation of
glycolic acid [81, 82]; however, lactic acid—probably the result
of the increased ratio of NADH/NAD—contributes importantly
to the acidosis and to the increased anion gap [82].
Ethylene glycol intoxication should be suspected in any
patient who appears drunk or comatose, who has a severe
metabolic acidosis with an increased anion gap, and who also
has an osrnolal gap. The finding of oxalate crystals in the urine
is a confirmatory finding, but a late one, and effective treatment
should not be delayed in its absence.
Treatment of ethylene glycol intoxication is similar to that for
methanol intoxication, and requires three types of intervention
in addition to the usual supportive maneuvers: the aggressive
correction of metabolic acidosis with sodium bicarbonate, the
achievement and maintenance of an adequate ethanol level
(approximately 100 mg/dl) [69, 71], and the institution of hemo-
dialysis using a bicarbonate bath [60, 70, 73, 79, 80, 821. With
this combination, even severe acidosis can be reversed, and the
metabolism of ethylene glycol is retarded while both the parent
compound and its toxic metabolites are effectively cleared by
dialysis [71. 79, 80, 82]. As in methanol poisoning, this aggres-
sive approach should be employed as soon as the diagnosis is
confirmed, and it should be implemented with the greatest
urgency, especially in the presence of metabolic acidosis.
Salicylates. Although salicylates are in part protein bound,
their relatively low apparent volume of distribution and molec-
ular weight (Table 6) suggest that extracorporeal methods
should be effective in substantially decreasing the total-body
burden of the drug in cases of severe intoxication. In fact, both
hemoperfusion and hemodialysis clear salicylate from the blood
[22]; however, hemodialysis is the superior method because of
the frequent association of salicylate poisoning with acid-base,
electrolyte, and extracellular fluid volume disturbances [83].
Acetylsalicylic acid (aspirin) is the form of salicylate most
commonly responsible for salicylate intoxication, although
methyl salicylate, sodium salicylate, and salicylic acid all cause
a similar clinical syndrome [84]. Aspirin, however, is unique
among the salicylates in its cyclooxygenase-inhibiting action,
which results from the acetylation of cyclooxygenase. Ulti-
mately, aspirin induces functional disturbances of platelets,
leads to decreased thromboxane production, and causes bleed-
ing disorders [84]. Salicylate poisoning accounts for approxi-
mately 10% of the deaths (Table 2) and 14% of the severe
intoxications (Table 5) recently seen in the United States. The
symptoms of the intoxicated patient differ depending on
whether the intoxication is acute or chronic [84, 85] and
whether the patient is an adult or a young child (less than 4
years of age) [84, 86, 87]. Nausea and vomiting, hyperventila-
tion, tinnitus, stupor, coma, and convulsions occur in all age
groups and in acute and chronic intoxications; fever and severe
metabolic acidosis are common in children but unusual in adults
[86. 88, 89]. Noncardiogenic pulmonary edema occurs predom-
inantly in adults and elderly patients with chronic salicylism,
especially if they have a history of smoking [85, 90—92].
Hypouricemia, induced by large salicylate doses, is more
common in chronic intoxication. The metabolic acidosis is
principally due to increased endogenous acid production, which
presumably is secondary to the salicylate-induced uncoupling
of oxidative phosphorylation [84], and only in minimal part due
to accumulation of salicylate [93]. The endogenous acids that
accumulate in salicylate poisoning have not been precisely
identified; lactate concentration is not greatly elevated, and
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ketoacids (which produce a positive ketone test) are elevated
mainly in infants with chronic salicylism [861. The diagnosis of
salicylate poisoning can be rapidly confirmed by the Phenistix:
when it is dipped in serum, a purple discoloration indicates a
salicylate concentration of at least 700 tg/ml [94].
The handling and metabolic fate of aspirin and its main
product of hydrolyzation, salicylic acid, are markedly influ-
enced by the amount of drug ingested. At normal therapeutic
dosages and blood levels, salicylate in plasma is about 90%
protein bound [951. It is largely glycinated to salicyluric acid
(75%), and only about 10% is excreted in the urine as salicylate
[84]. When taken in toxic doses, however, the plasma concen-
tration outstrips the capacity of albumin for binding, so that at
concentrations of 800 jig/mI, only about 50% of the drug is
protein bound [95]. Furthermore, the hepatic capacity to
biotransform salicylate into salicyluric acid is also easily satu-
rated [841. The combination of these two factors explains the
rapid increment in toxicity when therapeutic plasma levels are
exceeded. The increase in the "free" fraction of salicylate is
proportionally greater than that in the total plasma concentra-
tion; thus progressively larger amounts of the drug are available
to enter the interstitial fluid, cerebrospinal fluid, and intracellu-
lar compartment, where they exert their deleterious effects. At
the same time, an increasingly greater proportion of the drug
must be excreted by the kidney as salicylate, a less efficient
process than the excretion of salicyluric acid. This increases the
half-life of salicylate from 3—12 hours to 15—30 hours [84]. The
renal disposal of salicylate markedly depends not only on GFR,
but also on urine flow rate, and especially on urine pH [84, 96];
the induction of an alkaline urine (pH greater than 7.0) increases
salicylate excretion dramatically because of this compound's
acidic pK' and because of its inability to diffuse through cellular
membranes when in the ionized form [93].
Treatment of salicylate intoxication must rely on measures
that empty the gastrointestinal tract, on the administration of
activated charcoal, and on the usual supportive maneuvers that
ensure ventilation and appropriate hydration. Because of the
frequent association of hypokalemia and volume depletion with
salicylate poisoning, appropriate rates of fluid administration
are especially important. In the presence of high plasma con-
centrations of salicylate (approximately 500 jig/mI), measures
for alkalinizing the urine are warranted [93, 961. Usually sodium
bicarbonate is administered at rates sufficient to produce a urine
pH greater than 7.5. The administration of carbonic anhydrase
inhibitors alone is not recommended, because it usually is
ineffective in the presence of metabolic acidosis, and because it
can aggravate the hypobicarbonatemia if effective. Carbonic
anhydrase inhibitors can be employed in combination with
alkalinizing salts, however, after metabolic acidosis has been
corrected. Because the administration of sodium salts can result
in sodium retention and pulmonary edema [85, 93], an attempt
at making the urine alkaline with sodium bicarbonate occasion-
ally is unsuccessful or precipitates extracellular fluid overload.
In these circumstances, if coupled with high plasma salicylate
levels (>800 jig/mi), and especially in the presence of coma or
progressive clinical deterioration [83, 93], hemodialysis can be
employed to advantage. Despite the frequency of salicylate
intoxication, and despite this poison's pharmacologic charac-
teristics, which predict that hemodialysis should be highly
effective in removing substantial amounts of drug, only anec-
dotal information is available about the amount of drug re-
moved [83]. In any case, hemodialysis would be expected not
only to markedly decrease the total-body burden of salicylate,
but also to facilitate extracellular fluid volume control and the
repair of metabolic acidosis.
Lithium. In contrast to most other drug poisonings, acute
lithium intoxication usually results from chronic accumulation.
Thus, the clinical manifestations of toxicity (neuromuscular
hyperirritability, confusion, delirium, hyperpyrexia, stupor pro-
gressing to coma, nausea and vomiting, cardiac arrhythmias,
and hypotension and circulatory collapse [97, 98]) are often
superimposed on the side effects of chronic use of this drug.
These side effects include thyroid gland enlargement, usually
without clinical evidence of hypothyroidism, nephrogenic dia-
betes insipidus [99] and renal acidification defects [100] with
chronic interstitial nephritis [loll, and leukocytosis [97].
Lithium is commonly used for the treatment of manic-
depressive illness. Its usual formulation is lithium carbonate
(mol. wt. 74 daltons). The mechanism of action of lithium is
poorly understood, but it is thought to depend on the achieve-
ment of intracellular concentrations in the range of 1 mM. After
ingestion, lithium is promptly absorbed by the gastrointestinal
tract, and peak serum concentrations are reached in 2 to 4
hours. Because of its low atomic weight and absence of protein
binding (Table 6), lithium eventually gains access to the intra-
cellular fluid, and its final apparent volume of distribution is
similar to that of total-body water. Because lithium cannot
effectively substitute for sodium or potassium as a substrate for
sodium-potassium ATPase, a measurable lithium gradient
across cellular membranes cannot be established and main-
tained [97]. Because the transmembrane movement of lithium is
not immediate, several hours are required to achieve equilib-
rium between the extracellular and the intracellular compart-
ment following rapid administration or withdrawal of the drug
[971. Thus, the measurement of plasma levels should be delayed
for 10 to 12 hours after hemodialysis to assess the effect of this
treatment on total-body burden. Lithium eventually is almost
completely excreted via the kidneys [1021. Following filtration,
its rate of reabsorption by the proximal tubule is in the range of
75% to 80%. Lithium is influenced nonspecifically by all the
physiologic, pathologic, and therapeutic maneuvers that alter
proximal tubular reabsorption of sodium [103]. Thus, states of
extracellular fluid volume depletion or any condition that is
associated with increased renal avidity for sodium reabsorption
(including the use of nonsteroidal antiinfiarnmatory agents
[104]) increases lithium retention and may require a dosage
change. Because of the low therapeutic index of lithium and
because of the many circumstances that can cause substantial
changes in its rate of renal excretion, monitoring of serum
lithium levels is essential whenever lithium is used chronically.
Treatment of acute lithium poisoning largely depends on the
adequacy of renal function, but therapy must be aggressive
because of the seriousness of this condition, which produces a
10% mortality and an additional 10% rate of permanent neuro-
logic damage [981. In patients with mild symptoms, with a
serum level of lithium below 2.5 mM at least 12 hours after
ingestion, and in the presence of normal renal and cardiac
function, discontinuation of lithium carbonate and repair of
extracellular fluid volume depletion sometimes are sufficient.
Forced diuresis and the administration of large amounts of
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saline or osmotic agents have been associated with the devel-
opment of hypertonicity without a clear increase in lithium
excretion, and these therapies are not indicated [981. More
severe symptoms, higher serum levels (>2.5 mM), the presence
of renal insufficiency, or other conditions that cause increased
renal avidity for sodium and lithium reabsorption call for
hemodialysis [98, 105, 106]. Hemodialysis is highly effective in
the removal of lithium. During dialysis, the extraction ratio of
lithium is 90%, and serum levels decrease dramatically. How-
ever, because of the relatively slow equilibration of intracellular
and extracellular lithium, a "rebound" of serum levels occurs
following cessation of dialysis. This rebound can be obviated by
extending the duration of dialysis to 8 or even to 10 hours,
depending on the severity of the intoxication. Furthermore, the
high extraction ratio apparently applies to plasma, not to whole
blood, because the lithium contained inside red cells is not
readily dialyzed [106]. In any case, a recalculation of the data of
Hansen and Amdisen [98], using serum levels at equilibrium
(that is, several hours after the end of dialysis), shows that a
9-hour hemodialysis resulted in the removal of about 60% of the
total-body burden of lithium.
Theophylline. Used primarily for the treatment of bronchial
asthma or as a centrally acting stimulant of respiration, theoph-
ylline is most commonly available as aminophylline, the com-
plex formed between theophylline and ethylenediamine.
Aminophylline offers increased solubility and gastrointestinal
absorption over theophylline [1071. Only about 10% of theoph-
ylline is recovered unchanged in the urine; the remainder is
metabolized in the liver. The usual half-life of theophylline is
approximately 9 hours in the adult. Its half-life is prolonged in
the presence of liver disease and congestive heart failure,
concurrent administration of cimetidine or erythromycin, and
supratherapeutic doses, as well as in early infancy and prema-
turity; it is accelerated by smoking and by agents that increase
liver metabolism of drugs (phenobarbital, phenytoin) [107, 108].
A minimum plasma theophylline concentration of 5 .tg/ml is
necessary to observe a beneficial effect, and the usual recom-
mended therapeutic level is between 10 and 20 g/ml. Mild
toxicity occurs at plasma concentrations of 15 g/m1, and toxic
reactions occur in 75% of patients with plasma levels of 25
g/ml or greater [109]. Severe intoxication is marked by nausea,
vomiting, abdominal pain, cardiac arrhythmias, hypotension,
impaired consciousness, seizures, and cardiorespiratory arrest.
The development of seizures portends a poor prognosis; the
frequency of seizures correlates with serum levels of theophyl-
line and with a high mortality rate as well as with permanent
neurologic damage [110, III]. Generalized or focal convulsions
can occur at serum levels as low as 25 jg/ml. They occur with
greater frequency at concentrations of 40 tg/ml, and are almost
universal at concentrations greater than 100 g/ml [1121.
In plasma, theophylline is 60% protein bound [108]; the free
fraction distributes readily in interstitial fluid and in the intra-
cellular compartment, and the apparent space of distribution is
between 0.4 and 0.6 liters/kg body weight (Table 6) [107]. The
treatment of mild to moderate theophylline poisoning rests on
measures to maintain the airway, support the circulation, and
treat arrhythmias. The use of multiple oral doses of activated
charcoal has received increased attention, because it is quite
effective in decreasing theophylline's half-life [1131. (The sug-
gested dose is 15 g hourly in adults, for 6—12 hours depending on
theophylline blood levels, and 2.5—10.0 g hourly in children,
depending on body size. Other authors recommended 20 g
every 2 hours [122].) In severe intoxication, however, in which
underlying functional hepatic or cardiac abnormalities would be
expected to decrease endogenous theophylline clearance, more
aggressive measures to remove the drug appear warranted if the
patient is older than 60 years or if cardiac arrhythmias and/or
seizures are prominent. Both hemodialysis and hemoperfusion
have been evaluated extensively, and both methods are effec-
tive in removing theophylline. Hemodialysis (using a hollow
fiber dialyzer, blood flow rates between 180 and 250 mI/mm, and
a dialysate flow rate of 550 mI/mm) results in a plasma extrac-
tion ratio of 0.5, a dialysis clearance of 75—98 mI/mm, and, most
importantly, in the removal of 40% of the administered dose in
3 hours [114]. Hemoperfusion, either using resin cartridges
[1151 or activated charcoal cartridges [116—1211 is even more
effective than hemodialysis: extraction ratios vary from 0.6
[117] to 0.9 [121]. Plasma concentration decreases rapidly, with
concurrent improvement in symptoms of toxicity. Charcoal
cartridges tend to become saturated, however, and they should
be changed after approximately 2 hours. The total amount of
drug removed can be calculated using blood rather than plasma
flow rates, because erythrocyte theophylline concentration is
comparable to that of plasma, and because theophylline is as
efficiently extracted from erythrocytes as from plasma [121].
These data confirm the ease of transcellular movement of
theophylline and indicate that its plasma protein binding is quite
loose.
Hemodialysis and hemoperfusion are effective in removing
theophylline from the intoxicated patient, but the selection of
patients for these aggressive treatments remains problematic.
For example, Aitken and Martin believe that hemoperfusion
should be used only in patients " . . . who are unable to
tolerate oral medication [that is, oral charcoal in repeated
dosesi, or in whom serious toxic manifestations are present"
[11 11. These authors also claim that plasma levels of theophyl-
line do not correlate with clinical toxicity. Yet in their series of
54 patients treated without hemoperfusion, 4 died and an
additional 2 had serious, permanent neurologic sequelae [1131.
In the absence of definitive data, I therefore concur with the
approach recommended by Park et al [119] as modified by
Goldberg et a! [122]: hemoperfusion should be performed (1) in
those patients with severe acute theophylline intoxication who
have a serum level greater than 80 g/ml and (2) in patients with
chronic intoxication who have a serum level greater than 60
g/ml, who cannot tolerate oral charcoal, and who either are at
least 60 years of age or who have concomitant liver or heart
disease. Although some patients might be hemoperfused under
these guidelines who might have improved with only conserv-
ative therapy, the need for avoiding the development of
cardiorespiratory collapse and/or a neurologic catastrophe
probably justifies this approach until better selection criteria are
available. I also should note that hemodialysis, although not
quite as effective as hemoperfusion, can substantially increase
the rate of theophylline elimination and should be used for the
same indications when hemoperfusion is not available.
Let us now return to the patient described here. She fulfilled
several criteria of severe intoxication: she had been on chronic
theophylline therapy, she was 63 years old, and she had cardiac
irritability. No attempt was made to treat her with "gastroin-
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testinal charcoal dialysis" [8, 1131. Using the data provided, we
can calculate that approximately 1800 mg of theophylline was
removed during 4 hours of hemoperfusion (at a blood flow rate
of 200 mI/mm, the average A-V difference was 37.5 jxg/ml: 37.5
x 240 x 200/1000). If we assume an apparent space of distri-
bution of 40 liters in this obese woman whose initial serum
theophylline concentration was 60.7 xg/ml, the initial total-
body burden was in the range of 2400 mg. Thus, hemoperfusion
eliminated approximately three-fourths of the patient's total-
body burden of theophylline.
Other intoxicants potentially treatable with extracorporeal
therapies. In addition to the drugs and toxins I have described,
several other intoxicants are candidates for extracorporeal drug
removal. I will review these in brief, because the evidence in
favor of using extracorporeal depuration is weak.
In methotrexate (mol. wt. 454 daltons) intoxication, the usual
treatment is the administration of leucovorin. Methotrexate is
approximately 50% protein bound in plasma, is highly polar in
aqueous solution, and its apparent space of distribution is 1.0
liter/kg body weight [1231. It is excreted almost completely
intact via the renal route. Acute renal failure can develop
following methotrexate infusion, especially if the drug is given
in large amounts, and if a high flow of alkaline urine is not
maintained [124]. Methotrexate appears to distribute in body
fluids according to a multicompartmental model [125]. Accord-
ingly, whereas the fraction of the drug present in the circulation
is readily available to be extracted by hemoperfusion, the drug
that is sequestered in other compartments does not equilibrate
promptly with the extracellular fluid [126]. Thus hemoperfusion
promptly lowers plasma levels of methotrexate, but "rebound"
is characteristic [1261. Early work indicated that resin hemo-
perfusion was not likely to be clinically effective [126], but
in-vitro experiments suggested that charcoal hemoperfusion
might be more efficacious, as expected from the highly polar,
water-soluble characteristics of the drug [1261. Recently,
Molina et al proposed that in the presence of severe renal
failure, when methotrexate's half-life is greatly prolonged, the
use of charcoal hemoperfusion (coupled if necessary with
hemodialysis) might be an expeditious way of decreasing the
length of time and the amount of leucovorin required for
treating patients who had toxic methotrexate levels [127].
During a 6-hour combined hemoperfusion and hemodialysis,
methotrexate blood levels decreased from approximately 900 to
200 nM. Although the rate of decrease in plasma concentration
levels appeared to return to the same slope that prevailed before
hemoperfusion, no clear rebound occurred after discontinua-
tion of the procedure [1271. No measurements of total amount
of drug removed were given; an estimate from the available data
(assuming a blood flow rate of 200 mI/mm for 6 hours, a mean
plasma concentration during the procedure of 500 nM, and a
fractional extraction of 0.5), reveals that approximately 0.0 18
mmoles, or 8.2 mg, was extracted during the procedure. Be-
cause the patient had been given approximately 220 mg of
methotrexate, combined hemoperfusion and hemodialysis re-
moved only 3.7% of the administered dose. Whether the
removal of this amount of drug (coupled with a rapid decrease
in plasma levels) is clinically useful remains to be determined,
but it is clear that administration of leucovorin remains the
mainstay of treatment for methotrexate toxicity, even in the
presence of advanced renal failure.
We can apply a similar line of reasoning to the evidence
regarding treatment of procainarnide intoxication. This drug
can cause lethargy and confusion, disturbances of intraven-
tricular conduction, ventricular tachycardia, torsade de pointes
[128], hypotension, and cardiovascular collapse. After absorp-
tion, procainamide (mol. wt. 272 daltons) has an apparent
volume of distribution of 1.4 liter/kg body weight [1281; in
plasma, only about 20% is protein bound. Although in part
eliminated in the urine, procainamide is in large part converted
in the liver to N-acetylprocainamide (NAPA), a compound that
shares many of the therapeutic and toxic properties of the
parent compound, and one that is almost completely eliminated
via the renal route. The apparent space of distribution of NAPA
is similar to that of procainamide, but this metabolite has a
slower intercompartmental transfer rate [1291. Because of these
pharmacologic characteristics, NAPA tends to accumulate and
cause toxic effects in patients with renal failure [130]. In these
circumstances, neither peritoneal dialysis nor hemodialysis is of
benefit, but hemoperfusion is capable of achieving a clearance
rate of approximately 150 mI/mm [131]. With the data available,
we can calculate that the procedure removes little more than
10% of the total-body drug burden [132]. To compensate for the
slow intercompartmental transfer, which tends to thwart the
effectiveness of procedures employed over short periods, con-
tinuous arteriovenous hemofiltration or hemodiafiltration
(CAVH) has been proposed [133]. This method increasingly is
being used for the treatment of patients with renal failure who
present special problems in the maintenance of the volume and
composition of body fluids [134]. Because CAVH can be
employed continuously and results in the exchange of large
volumes of fluid, it can remove a substantial amount of drug,
both at therapeutic and toxic concentrations [134, 135].
Whereas CAVH clearly can reduce NAPA levels more rapidly
than does chronic intermittent hemodialysis [133], the position
of CAVH in the therapeutic armamentarium of acute poison-
ings remains to be defined. This technique should be capable of
effectively increasing the rate of removal of many of the drugs
that are known to manifest tight tissue binding or to have slow
intercompartmental transfer.
Summary and conclusions
The notion that extracting the responsible toxins from the
plasma should dramatically improve the prognosis of patients
suffering from drug poisoning has a powerful instinctive appeal.
In recent years, techniques have been developed that have an
extraordinarily high efficiency in removing drugs from plasma.
Hemodialysis and, even more impressively, hemoperfusion can
achieve drug clearance rates that approach blood flow rates
through the extracorporeal circuit.
Two major lines of evidence can be used to assess the clinical
effectiveness of hemodialysis or hemoperfusion in the treatment
of patients with drug poisoning. Does the procedure reduce
morbidity or decrease mortality rates? In the absence of solid
data on this first question, does the procedure remove a
substantial fraction of the poison? Hemodialysis and hemoper-
fusion have not been shown to fulfill either criterion for most
intoxications. The prognosis of the patient who suffers from
drug poisoning appears to be largely determined by the time the
patient is first seen at a hospital [2, 12, 136]. By that time, most
complications of the poisoning already have developed, and if
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the patient has already suffered a major complication, such as a
prolonged cardiorespiratory arrest leading to anoxic brain dam-
age, its consequences will not be reversed by aggressive drug
removal. On the other hand, if the patient has reasonably stable
cardiorespiratory function, appropriate supportive measures
usually are sufficient to achieve survival and prevent long-term
sequelae. Despite their often dramatic and apparently hopeless
condition, only a very small fraction of patients with drug
poisoning who reach the hospital die. Thus it is not surprising
that the use of hemodialysis or hemoperfusion is associated
with a low mortality rate. Only the performance of a lengthy
and complicated controlled study could establish the clinical
usefulness of these procedures, and such a study has not been
performed. Lacking clinical criteria to judge the effectiveness of
hemodialysis or hemoperfusion, we can turn to pharmacoki-
netic principles. It is apparent that despite excellent rates of
plasma clearance and extraction ratios, neither procedure can
remove substantial amounts of most toxins, because most drugs
either have very high apparent volumes of distribution, unfa-
vorable tissue binding characteristics, or both 12, 137, 138].
Most poisonings with common intoxicants are best treated
with supportive measures only and should be supplemented by
attempts at emptying the gastrointestinal tract and preventing
further absorption. On occasion, "gastrointestinal charcoal
dialysis" or attempts at increasing urinary elimination also can
be useful. Few exceptions to these recommendations exist, and
they pertain to intoxications with drugs that have a low appar-
ent volume of distribution and low tissue binding, especially
when toxicity results in the formation of compounds that have
a more prolonged half-life and greater toxicity than the parent
drug. In severe intoxications with isopropanol, methanol, and
ethylene glycol, hemodialysis is effective in removing the
parent drug and its noxious metabolic products, as well as in
contributing to the repair of acid-base alterations. Even in
methanol and ethylene glycol poisoning, dialysis, although
important, is an adjunctive measure to the administration of
ethanol for retarding the metabolic production of compounds
more toxic than the parent drug. In cases of severe salicylate
intoxication, hemodialysis should be employed if renal function
is not adequate, if an alkaline diuresis cannot be established, or
if metabolic acidosis and fluid overload develop. Lithium intox-
ication, when life-threatening, also sometimes requires dialysis,
especially if renal failure coexists. Finally, theophylline poison-
ing can be benefited by hemoperfusion or, if hemoperfusion
expertise and equipment are not readily available, by hemodi-
alysis. The clinical usefulness of hemodialysis and hemoperfu-
sion in all other indications remains to be proven.
Questions and answers
DR. DENNIS SLOAN (Attending Physician, Michael Reese
Hospital): Many hospitals (10 not have the facilities to perform
hemodialysis using single-pass systems; instead they use the
Sorbsystem. A disadvantage of this system is its limited capac-
ity to absorb toxins. In such a setting, would an attempt at
hemoperfusion be appropriate for treating a patient who has
alcohol or severe theophylline poisoning?
DR. GARELLA: One of the five layers of the Sorbsystem
cartridge contains approximately 230 g of activated carbon, and
at first sight one would think that it might be as effective as the
hemoperfusion devices in adsorbing toxins. However, in con-
trast to these devices, the cartridge is designed to regenerate the
dialysate, not to allow the blood to come in direct contact with
the adsorbent surfaces. A given toxin therefore first must
traverse the dialysis membrane, be diluted in the small amount
of dialysate available, and then be adsorbed in the cartridge. If
the toxin reached the layer of activated carbon in sufficient
amounts, presumably it would be adsorbed very efficiently; I
am not aware of any study that demonstrates the clinical
effectiveness of the Sorbsystem in exogenous intoxications.
The alcohols almost certainly would not be removed efficiently,
because they need a large volume of fluid to diffuse into, and
they are not well adsorbed by activated carbon or charcoal.
They therefore are not good candidates for treatment with
hemoperfusion either. Theophylline instead does seem to be
removed quite rapidly by hemoperfusion.
DR. SATISH KUMAR (Renal Fellow, Joint Michael Reese!
University of Chicago Nephrology Program): Does peritoneal
dialysis have a place in the treatment of theophylline poisoning?
Dg. GARELLA: Theophylline is a relatively small molecule
that is not protein bound, and it would traverse the peritoneal
membrane quite readily. The extent of its removal would
depend on the rapidity and volume of the exchange of perito-
neal dialysate. Assuming that a 2 liter exchange could be
performed every 30 minutes and that complete equilibration of
theophylline between plasma and peritoneal dialysate could be
achieved in this time, the amount of theophylline removed
would be that contained in 4 liters of plasma every hour. In a
patient with a theophylline level of, say, 60 xg/ml, this would
correspond to the removal of 240 mg!hr. This rate of removal is
too small compared to spontaneous excretion to have a favor-
able impact on prognosis [122, 139].
DR. STUART SPRAGUE (Renal Fellow, Joint Michael
Reese!University of Chicago Nephrology Program): If one
considers the higher blood flows obtainable with hemodialysis,
does hemoperfusion offer an advantage in treating theophylline
toxicity?
DR. GARELLA: As I mentioned before, hemodialysis is indeed
a possible substitute for hemoperfusion in patients with
theophylline intoxication who are thought to warrant treatment
with extracorporeal methods. However, I believe that it is not
the treatment of choice. There are two major reasons for this
conclusion: first, theophylline is present in plasma and in red
blood cells in almost equal concentrations. Charcoal hemoper-
fusion is capable of extracting theophylline as efficiently from
plasma as from red blood cells [21]; thus, the total amount of
drug removed depends on blood flow rather than on plasma
flow. There are no data on whether dialysis extracts theophyl-
line as efficiently from red blood cells. Second, cardiac ar-
rhythmias and hemodynamic instability are major problems in
patients with severe theophylline toxicity, and they are more
likely to be aggravated by hemodialysis than by hemoperfusion,
which appears to be less prone to cause hypotension and
hemodynamic instability [23, 24, 122].
DR. JORDAN J. COHEN (Chairman, Department of Medicine,
Michael Reese Hospital): You mentioned the 'toxic compart-
ment" concept as a possible explanation for why patients
intoxicated with tricyclic antidepressants have been thought to
respond well to hemoperfusion. It seems to me that suitably
designed animal studies could establish whether such a "toxic
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compartment" exists. Has this question been looked at system-
atically in animal models of intoxication?
DR. GARELLA: The pharmacokinetics of many drugs have
been studied in great detail, especially as regards their binding
properties, their ease of intercompartmental transfer, and their
distribution. However, I am not aware of studies perfirmed
specifically to elucidate the validity of this concept [361. Per-
haps this is due to technical difficulties, or perhaps to the fact
that it might be too complicated to correlate the amount of drug
removed from different tissues or different organs to the "clin-
ical responses" of the experimental animal.
DR. JASON UMANS (Renal Fellow, Joint Michael Reese!
University of Chicago Nephrology Program): The data you
presented, based on pharmacokinetic approaches developed
more than 20 years ago, should he reconsidered in light of the
subsequent development of more sophisticated and powerful
kinetic models. Models such as those of Sheiner et al [140],
relating drug effect and concentrations in multiple compart-
ments, as opposed to the one-compartment data you have
presented, may allow us to better examine the efficacy of
hemoperfusion and the relevance of a 'toxic" compartment.
Such newer approaches certainly would suggest that studies
based on symptom severity are ill-conceived and unlikely to
yield useful conclusions, that more powerful experiments
would be based on the consideration of each individual drug's
pharmacokinetic and pharmacodynamic characteristics, and
that the actual clinical procedure of hemoperfusion might not be
integral to the study. One should examine known multiple
compartment pharmacokinetic data, noting the rate constants
that determine drug efflux from the compartments with which
drug effect is apparently associated. Then one can directly
calculate the effect of acute drug removal from a more central
compartment on drug concentration in the compartment best
related to the intensity of drug effect. This approach, using
known drug-specific multicompartment kinetic and protein-
binding data and dialysis!hemoperfusion clearance rates, obvi-
ates the need to do cumbersome, expensive, and likely incon-
clusive clinical trials of hemoperfusion in poisoning.
DR. GARELLA: If you are saying that it would be desirable to
characterize more completely the kinetic and dynamic behavior
of all toxins, or for that matter, of all drugs, and to describe in
detail not only their mode of action, but their metabolism,
distribution in various tissues, ease of intercompartmental
transfer, binding properties, and the qualitative and quantitative
qualities of their interaction with their 'target" organ or cell,
then I fully agree with your statement. It is mostly through
advances in this area of study that we have begun to understand
better not only the treatment of intoxications, but the proper
use of drugs in general. It was not too long ago that dosing
intervals of drugs, or even total amount of administered drug,
were decided almost exclusively according to blood or plasma
levels; now we are finally beginning to understand that in many
cases—such as aminoglycosides or beta blocking agents—it is
the tissue level or the intracellular concentration that may be
more important from the toxicologic as well as from the
therapeutic viewpoint. So there is no contention about the need
for more knowledge on drug behavior.
I disagree with the concepts that you expressed in the latter
part of your statement, however, namely whether such refined
knowledge of drug action would obviate the need for clinical
trials that would judge the effectiveness of hemoperfusion, or of
any other therapeutic maneuver. I believe that such detailed
pharmacokinetic and pharmacodynamic data would be useful
merely in predicting the plausibility of the clinical effectiveness
of such a maneuver. For example, if we could show that a given
drug manifests prompt binding to its target cells, and that the
binding of the toxin with the cells is irreversible, or that these
cells are destroyed within a very short time of contact with the
toxin, then we could predict that the therapeutic maneuver
under study would not be likely to be clinically effective. On the
other hand, let us say that study of the toxin or drug shows that
it does not cause irreversible binding or cell necrosis, and that
the drug bound to its target organ is in immediate equilibrium
with the extracellular fluid from which it can be removed
efficiently. Does this observation predict that therapy would be
efficacious? Not at all. If the patient has sustained severe
functional damage to the brain because of, say, arrhythmias or
hypotension during the initial stages of poisoning, then even the
prompt removal of the toxin will not improve the prognosis. In
these circumstances, the pharmacologic prerequisites exist for
the procedure to be potentially efficacious; whether or not it
would be shown to be beneficial still would depend on the
results of clinical trials. I therefore fear that clinical trials,
admittedly expensive and cumbersome, are still necessary
before we can reach a conclusion. They must be performed in a
focused manner, looking at the effects of a given procedure on
a well-defined group of patients intoxicated with a specified
toxin. However, the data available to us show, in my opinion,
that evidence for the clinical effectiveness of hemoperfusion in
the majority of intoxications, even the most severe, is lacking.
Even animal experimentation would fall short of the goal:
species differences and the presence of standardized circum-
stances would prevent a translation of results obtained from
animal studies to the clinical situation. Yet such studies would
at least help in establishing the possibility of a therapeutic
effect, and would describe the magnitude of the time interval or
size of the toxic dose beyond which intervention would likely
be either unnecessary or futile.
DR. FREDRIC C0E (Director, Joint Michael Reese!University
of Chicago Nephrology Pro grain): Do you believe the patient
we are discussing needed hemoperfusion? What criteria should
we use in selecting patients with theophylline intoxication who
should be treated this way? Do you make a distinction between
patients with overdose due to voluntary ingestion and those
with iatrogenic overdose? Rather large overdoses can occur in
the latter instance.
DR. GARELLA: You are asking the crucial question, the one
that the clinician has to answer. Let me first say that in general
I do not believe that we should rely on the blood level of any
given drug as the sole criterion for deciding on a course of
therapy. Blood levels by themselves are just not that predictive
of severity of intoxication or of morbidity or mortality rates
150—52]. We therefore must develop criteria for therapeutic
intervention that are based on a constellation of historic find-
ings, symptoms and signs, and chemical analyses that can be
considered together to reach a decision. The information avail-
able on theophylline intoxication is not yet firm and compre-
hensive enough for us to be sure about our criteria. On the basis
of uncontrolled clinical observations. Park et al have proposed
criteria for the use of hemoperfusion that, although certainly
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not definitive, seem to me quite reasonable [119, 1221. They
would use hemoperfusion in patients with a blood level (I)
greater than 80 jsg/ml, (2) greater than 60 rg/ml if the intoxica-
tion is chronic (including iatrogenic toxicity), or (3) greater than
50 sg/ml if the patient is more than 60 years of age, has liver or
heart disease, and is unable to tolerate oral therapy with
repeated doses of activated charcoal [1221. These criteria were
offered in the belief that the development of seizures carries a
grave prognosis, and that therapy with hemoperfusion, to be
beneficial, must be instituted before the occurrence of this
complication. Although no consensus exists on the appropri-
ateness of these guidelines [1111, I believe at this time that the
prudent physician should choose the relatively low risk of
hemoperfusion in a patient who fulfills the criteria just outlined,
rather than taking a less aggressive attitude. Patients with
iatrogenic intoxication seem to be more likely to develop
complications at lower blood levels; I suppose this reflects the
fact that, by and large, they are older and more likely to be
suffering from underlying renal, liver, and cardiac disease than
are the people who have acute intentional overdose.
Does that mean that the patient described here should nec-
essarily have undergone hemoperfusion? I believe that this
patient could have done quite well with orally administered
activated charcoal. Perhaps she would have done well with no
therapy at all. But that is not the question: the real question is:
if we had 100 patients with a degree of intoxication comparable
to that of the patient described here, would they do better on
the average, with lower morbidity and mortality rates, with or
without hemoperfusion? I believe that at this time the weight of
the evidence, although admittedly preliminary, favors hemoper-
fusion.
DR. ARNOLD BERNS (Attending Nephrolo gist, Michael Reese
Hospital): You suggest that hemoperfusion might be useful in
the management of theophylline overdose. Published informa-
tion seems to support this position. However, the literature
seems to identify two groups of patients with serious theophyl-
line overdosage [119, 1221. One group is hemodynamically
stable and tolerates hemodialysis and hemoperfusion well. A
second group is not hemodynamically stable and does not
tolerate hemodialysis or hemoperfusion well. There is clearly a
lower mortality in the former than in the latter group. but this
difference might be related more to the clinical severity of the
overdose and its attendant hemodynamic instability than to the
treatment. Therefore, extracorporeal therapy might not be
useful in the management of theophylline overdose, and per-
haps the prudent physician should not utilize such therapy until
controlled studies demonstrate a more definite benefit.
DR. GARELLA: You are correct in pointing out that the data
on which the recommendation to use hemoperfusion in
theophylline overdose are based are not properly controlled.
There were two groups of patients—indeed, three—and they
were not comparable [119]. As the authors themselves recog-
nized [122], there is a need for a properly performed controlled
study that will allow us to better define not only which patients
should be hemoperfused, but even more basically, to determine
whether hemoperfusion is to be employed at all in this intoxi-
cation. You highlight the usual difficulties of interpretation of
retrospective uncontrolled studies. Patients who are more sta-
ble, and less ill to begin with, can withstand hemoperfusion and
are more likely to do better than are more seriously ill people.
We need the empiric data to proceed with a formal clinical
decision analysis: then we will be able to predict which ap-
proach leads to a better prognosis. In the absence of such
information, I for one would go ahead with hemoperfusion in
patients with severe theophylline intoxication; but I would not
in the least be surprised if more precise data will ultimately
deny the usefulness of hemoperfusion even in this poisoning.
DR. PAUL SACKS (Renal Fellow, Joint Michael Reese! Uni-
versity of Chicago Nephrology Program): What are the serious
complications of hemoperfusion?
DR. GARELLA: In actuality, they are relatively few when
modern cartridges are used. Complications that are specific to
hemoperfusion include a drop in platelet count that averages
about 30%, but that rarely causes bleeding; hypoglycemia and
some decrease in the white blood cell count can occur. Other
complications are common to all methods that require
extracorporeal blood circulation, and include bleeding due to
heparinization, the possibility of infection at the blood access
site, bacteremia. and hypotension due to hemodynamic
changes. The last seems less common than in hemodialysis. In
my opinion, however, the major side effect of hemoperfusion is
that it can focus attention on the procedure and diminish the
likelihood that the patient will receive appropriately attentive
supportive care, including careful monitoring and assistance of
ventilation and circulation, moving the patient from side to side,
and monitoring and modification of fluid intake and output.
DR. KUMAR: Is hypocalcemia a serious problem?
DR. GARELLA: Apparently not. Although it occurs with
hemoperfusion, it usually is mild and not symptomatic.
DR. MARK RICHTER (Staff Nephrolo gist, Mitchell Hospital):
How would you treat a hernodialysis patient who has severe
digoxin intoxication? Would hemoperfusion be effective as an
adjunct to therapy with antibody?
DR. GARELLA: You are referring to the problem of release of
digoxin from the digoxin/antibody complex. I suppose this
could be a serious problem in the patient with renal failure who
cannot excrete the free digoxin a little at a time as it becomes
available. I must speculate now, because I am not familiar with
studies that address this particular situation. I would imagine
that the digoxin released from its antibody, because it cannot be
excreted, would fix to its target organ, mainly the myocardial
cells, and potentially reproduce the toxicity. Simply continuing
hemodialysis would not be very effective in increasing its
excretion: neither would performing hemoperfusion. It is con-
ceivable that this might be a situation in which continuous
arteriovenous diafiltration might turn out to be useful, as it
might permit the slow removal of the free digoxin over a period
of time. Another approach might be that of considering plas-
mapheresis early, in that this technique would actually remove
the digoxin/antibody complex before it releases digoxin.
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